Extensive Stage Small Cell Lung Cancer Clinical Trial
Official title:
Lobaplatin Combined With Etoposide for First-line Treatment in Extensive Stage Sclc Then Benefit Patients Follow up Temozolomide Maintain Therapeutic
This study evaluates temozolomide maintain therapeutic efficacy and safety in extensive stage SCLC who has clinical benefit from etoposide combined Los platinum (EL) scheme in the first line treatment.
According to the etoposide combined Los platinum (EL) plan administration, every cycle was 21 days, a total of four cycle. The patients who was clinical benefit directly from EL scheme in the first line treatment accept temozolomide maintenance therapy, 150mg / m2, oral D1-5. A period of 28 days, regular follow-up and evaluation of effectiveness, safety and quality of life. ;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05903092 -
MOnaliZumab in Combination With durvAlumab (MEDI4736) Plus Platinum-based chemotheRapy for First-line Treatment of Extensive Stage Small Cell Lung Cancer
|
Phase 2 | |
Completed |
NCT01935336 -
Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers
|
Phase 2 | |
Completed |
NCT00544596 -
R-(-)-Gossypol Acetic Acid, Cisplatin, and Etoposide in Treating Patients With Advanced Solid Tumors or Extensive Stage Small Cell Lung Cancer
|
Phase 1 | |
Active, not recruiting |
NCT04063163 -
A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of HLX10 + Chemotherapy (Carboplatin- Etoposide) in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)
|
Phase 3 | |
Terminated |
NCT01217411 -
RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer
|
Phase 1 | |
Completed |
NCT00773955 -
R-(-)-Gossypol Acetic Acid in Treating Patients With Recurrent Extensive-Stage Small Cell Lung Cancer
|
Phase 2 | |
Completed |
NCT00528645 -
AZD0530 in Treating Patients With Extensive Stage Small Cell Lung Cancer
|
Phase 2 | |
Recruiting |
NCT05468489 -
To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC
|
Phase 2 | |
Active, not recruiting |
NCT00828139 -
Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer
|
Phase 2 | |
Recruiting |
NCT05896059 -
A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Anlotinib as Maintenance Therapy for ES-SCLC
|
Phase 2 | |
Recruiting |
NCT04346914 -
Study of ZKAB001 Combined With Carboplatin and Etoposide in the Extensive Small Cell Lung Cancer
|
Phase 1 | |
Recruiting |
NCT06323265 -
A Real-world Study of Adebrelimab Combined With Chemotherapy±Chest Radiotherapy in Patients With Extensive Stage Small Cell Lung Cancer
|
||
Withdrawn |
NCT01325753 -
Cryotherapy in Treating Patients With Lung Cancer That Has Spread to the Other Lung or Parts of the Body
|
N/A | |
Completed |
NCT00019006 -
Vaccine Therapy in Treating Patients With Colon, Pancreatic, or Lung Cancer
|
Phase 1 | |
Not yet recruiting |
NCT04933175 -
Fluzopalil in Combination With Anlotinib for Extensive Small-cell Lung Cancer
|
Phase 2 | |
Completed |
NCT01331525 -
The Addition of Ipilimumab to Carboplatin and Etoposide Chemotherapy for Extensive Stage Small Cell Lung Cancer
|
Phase 2 | |
Completed |
NCT01155258 -
Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors
|
Phase 1 | |
Terminated |
NCT00088933 -
Vaccine Therapy and Sargramostim With or Without Docetaxel in Treating Patients With Metastatic Lung Cancer or Metastatic Colorectal Cancer
|
Phase 1 | |
Completed |
NCT00020202 -
FR901228 in Treating Patients With Refractory or Progressive Small Cell Lung Cancer or Non-small Cell Lung Cancer
|
Phase 2 | |
Completed |
NCT02194049 -
Cisplatin, Etoposide and PI3K Inhibitor BKM120 in Treating Patients With Advanced Solid Tumors or Small Cell Lung Cancer
|
Phase 1 |